A 63-year-old woman comes to the clinic for follow-up of heart failure diagnosed 4 months ago after an anterior myocardial infarction. She has dyspnea when climbing two flights of stairs but none at rest, and no orthopnea or paroxysmal nocturnal dyspnea. Medications are lisinopril 20 mg daily, carvedilol 25 mg twice daily, atorvastatin, and aspirin. She does not smoke or drink alcohol. Her pulse is 64/min and blood pressure is 118/72 mm Hg; weight is unchanged from 3 months ago. Jugular venous pressure is 6 cm H2O. Lungs are clear. There is no S3 and no peripheral edema. Laboratory studies show sodium 139 mEq/L, potassium 4.3 mEq/L, and creatinine 1.0 mg/dL (estimated GFR 68 mL/min/1.73 m2). Echocardiography 2 weeks ago showed a left ventricular ejection fraction of 30%. Which of the following is the most appropriate addition to her regimen?
- Digoxin
- Diltiazem
- Furosemide
- Amlodipine
- Spironolactone
Show the answer and explanation
Correct answer: E. Spironolactone
She has heart failure with reduced ejection fraction (LVEF 30%) and NYHA class II symptoms despite an ACE inhibitor and an evidence-based beta blocker at target dose. A mineralocorticoid receptor antagonist reduces mortality and hospitalization in symptomatic HFrEF (LVEF ≤35%) when potassium is <5.0 mEq/L and eGFR is >30 mL/min/1.73 m2, both of which she meets. She is euvolemic, so a loop diuretic is not indicated, and nondihydropyridine calcium channel blockers worsen outcomes in HFrEF.
Why each option is right or wrong
- DigoxinDigoxin reduces hospitalizations but not mortality and is reserved for persistent symptoms after guideline-directed therapy.
- DiltiazemDiltiazem is a negative inotrope that worsens outcomes in HFrEF and should be avoided.
- FurosemideFurosemide relieves congestion but she is euvolemic and diuretics do not improve survival.
- AmlodipineAmlodipine is neutral in HFrEF and offers no benefit for a normotensive patient.
- SpironolactoneCorrect: spironolactone provides a mortality benefit in symptomatic HFrEF with adequate potassium and renal function.
In symptomatic HFrEF with K+ <5.0 and eGFR >30, add a mineralocorticoid receptor antagonist for mortality benefit; avoid nondihydropyridine calcium channel blockers.
References
- Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction (Eur Heart J 2012 (PubMed 22942339))